ArchiveJune 2014

How to treat

Treatment paradigms in multiple sclerosis: who, when and how to treat? Willis MD, Robertson NP. J Neurol. 2014 Jun. [Epub ahead of print] With an increasing array of disease-modifying therapies (DMTs) for multiple sclerosis (MS) now available, clinicians are faced with a range of difficult treatment decisions relating to patient selection, timing of interventions and response to treatment...

How to measure nerve damage using the eye

Schippling S, Balk L, Costello F, Albrecht P, Balcer L, Calabresi P, Frederiksen J, Frohman E, Green A, Klistorner A, Outteryck O, Paul F, Plant G, Traber G, Vermersch P, Villoslada P, Wolf S, Petzold A. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler. 2014 Jun 16. pii: 1352458514538110. [Epub ahead of print] BACKGROUND:Retinal...

Massage feel better

Schroeder B, Doig J, Premkumar K. The effects of massage therapy on multiple sclerosis patients’ quality of life and leg function. Evid Based Complement Alternat Med. 2014;2014:640916. doi: 10.1155/2014/640916. Epub 2014 May 8. Background. Massage therapy is a noninvasive treatment that many individuals with multiple sclerosis (MS) use to supplement their conventional treatment. ...

T reg cells

Kasagi S, Zhang P, Che L, Abbatiello B, Maruyama T, Nakatsukasa H, Zanvit P, Jin W, Konkel JE, Chen W. In vivo-generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response. Sci Transl Med. 2014 Jun 18;6(241):241ra78. Harnessing regulatory T (Treg) cells is a promising approach for treating autoimmune disease. However, inducing...

A molecule that blocks remyelination

Tepavčević V, Kerninon C, Aigrot MS, Meppiel E, Mozafari S, Arnould-Laurent R, Ravassard P, Kennedy TE, Nait-Oumesmar B, Lubetzki C.Early netrin-1 expression impairs central nervous system remyelination. Ann Neurol. 2014 Jun. doi: 10.1002/ana.24201. [Epub ahead of print] Objective: Chronically demyelinated multiple sclerosis (MS) lesions are frequently characterized by scarce...

sexual Dysfunction in Women with mS

Ashtari F, Rezvani R, Afshar H.Sexual dysfunction in women with multiple sclerosis: Dimensions and contributory factors. J Res Med Sci. 2014;19(3):228-33 BACKGROUND:Sexual dysfunction (SD) is a common reported problem in patients with multiple sclerosis (MS). AIMS:to examine frequency and distribution of SD dimensions and to determine whether SD is related to various clinical and demographic...

Measuring Brain Shrinkage

Gao KC, Nair G, Cortese IC, Koretsky A, Reich DS. Sub-Millimeter Imaging of Brain-Free Water for Rapid Volume Assessment in Atrophic Brains.Neuroimage. 2014 Jun 16. pii: S1053-8119(14)00491-1. INTRODUCTION: Cerebral atrophy occurs in healthy aging, and in disease processes such as multiple sclerosis (MS), it correlates with disability accumulation. Imaging measurements of brain atrophy are...

Mice are not men

Noster R, Riedel R, Mashreghi MF, Radbruch H, Harms L, Haftmann C, Chang HD, Radbruch A, Zielinski CE. IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells. Sci Transl Med. 2014 Jun 18;6(241):241ra80 Although T helper 17 (TH17) cells have been acknowledged as crucial mediators of autoimmune tissue damage, the effector cytokines responsible for their pathogenicity...

Is inflammation in the MS the same as in other neurodegenerative diseases

Filiou MD, Arefin AS, Moscato P, Graeber MB. ‘Neuroinflammation’ differs categorically from inflammation: transcriptomes of Alzheimer’s disease, Parkinson’s disease, schizophrenia and inflammatory diseases compared. Neurogenetics. 2014 Jun 15. [Epub ahead of print] Neuroinflammation’ has become a widely applied term in the basic and clinical neurosciences but there...

One Me-Too bites the Dust for the moment

Ceralifimod is a sphingosine-1-phosphate (S1P) receptor-1 and -5 agonist and was licensed by Merck in 2011 for development outside Japan, Korea and Taiwan.  Merck apparently said in a statement that ceralifimod (ONO-4641) “does not meet Merck’s threshold for continued investment”. So this new drug set to compete against fingolimod/Gilenya is put back on the self as Merck...

Translate

Categories

Recent Posts

Recent Comments

Archives